Sugi Predict

Sugi Predict / Targets / SYK

SYK

Tyrosine-protein kinase SYK · P43405 · SYK on Sugi Atlas →

282,303 patent compounds predicted against SYK, 156,331 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL190375 SCHEMBL190375 0.70 18/20
SCHEMBL24327 SCHEMBL24327 0.56 15/20
SCHEMBL191238 SCHEMBL191238 0.54 14/20
Delavirdine Delavirdine (SCHEMBL34420) 0.47 14/20
Delavirdine Delavirdine (SCHEMBL40522) 0.46 14/20
SCHEMBL144714 SCHEMBL144714 0.64 13/20
SCHEMBL190515 SCHEMBL190515 0.61 12/20
SCHEMBL140075 SCHEMBL140075 0.56 12/20
SCHEMBL24615 SCHEMBL24615 0.53 12/20
SCHEMBL20079 SCHEMBL20079 0.50 12/20
SCHEMBL144871 SCHEMBL144871 0.56 10/20
SCHEMBL141036 SCHEMBL141036 0.53 10/20
Mephenoxalone Mephenoxalone (SCHEMBL5392) 0.59 9/20
SCHEMBL68696 SCHEMBL68696 0.53 9/20
SCHEMBL21062 SCHEMBL21062 0.47 9/20
SCHEMBL146914 SCHEMBL146914 0.52 7/20
SCHEMBL46662 SCHEMBL46662 0.39 7/20
SCHEMBL169753 SCHEMBL169753 0.62 6/20
SCHEMBL23412 SCHEMBL23412 0.53 6/20
SCHEMBL84157 SCHEMBL84157 0.50 6/20

Clinical trials — most relevant to SYK by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Fostamatinib for Hospitalized Adults With COVID-19 PHASE2COMPLETED
Erlotinib Hydrochloride in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia PHASE2COMPLETED
Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL PHASE2RECRUITING
Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell Lymphoma PHASE2COMPLETED
Orelabrutinib in Combination With R2 Regimen for R/R CD20+ B-cell Lymphoma PHASE2UNKNOWN
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma PHASE2COMPLETED
Study of Tirabrutinib (ONO-4059) in Patients With Primary Central Nervous System Lymphoma (PROSPECT Study) PHASE2ACTIVE_NOT_RECRUITING
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemia PHASE2COMPLETED
A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies PHASE1/PHASE2RECRUITING
PCI-32765 for Special Cases of Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma PHASE2ACTIVE_NOT_RECRUITING
Study on Treatment Outcome Patterns for Patients With CLL After Discontinuation of BTK Inhibitors PHASE2NOT_YET_RECRUITING
Safety and Efficacy of Zanubrutinib in the Treatment of Antiphospholipid Syndrome With Secondary Thrombocytopenia PHASE2RECRUITING
Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria PHASE1COMPLETED
A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia PHASE1COMPLETED
Evaluation of Fostamatinib in Patients With cGVHD After Allogeneic Stem Cell Transplant PHASE1COMPLETED
CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia PHASE1NOT_YET_RECRUITING
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia PHASE1COMPLETED
A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE1COMPLETED
Pacritinib and Chemotherapy in Treating Patients With Acute Myeloid Leukemia and FLT3 Mutations PHASE1COMPLETED
A Clinical Trial to Evaluate Safety of Gusacitinib in Patients With Systemic Lupus Erythematosus (SLE) or Lupus PHASE1WITHDRAWN
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia PHASE1NOT_YET_RECRUITING
A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia PHASE1COMPLETED
A Clinical Study Evaluating the Safety and Preliminary Efficacy of Universal Allogeneic CAR T-cell Therapy Targeting CD19 and BCMA(QT-019C)in Patients With Refractory Primary Immune Thrombocytopenia EARLY_PHASE1NOT_YET_RECRUITING
A Study of the Absorption, Metabolism, and Excretion of [14C]-SKI-O-703 Following a Single Oral Dose in Healthy Male Subjects EARLY_PHASE1COMPLETED
Pathogenesis of BTK-mediated Hyper-Inflammatory Responses in COVID-19 (RESPOND) nanWITHDRAWN
Andalusian Experience in the Use of Fostamatinib in Patients With ITP. FOSTASUR Study nanCOMPLETED
Esprit BTK Post-Approval Study nanACTIVE_NOT_RECRUITING
Ibrutinib Adapted to Response in Patients With CLL nanUNKNOWN
Current Status of BTKi Treatment for CLL/SLL in China nanRECRUITING
A Multi-center Clinical Study of Zanubrutinib in Combination With First-line Chemoimmunotherapy in Patients With Grade 3A High-risk Follicular Lymphoma nanACTIVE_NOT_RECRUITING

Related proteins — ESM-2 sequence neighbours (a SYK binder may also engage these)

ProteinNameSimilarity
Q64725 — 1.000 Q64725 →
P48025 — 1.000 P48025 →
Q00655 — 1.000 Q00655 →
P43404 — 0.999 P43404 →
F1N9Y5 — 0.998 F1N9Y5 →
ZAP70 Tyrosine-protein kinase ZAP-70 0.996 landscape →
BMX Cytoplasmic tyrosine-protein kinase BMX 0.994 landscape →
TXK Tyrosine-protein kinase TXK 0.992 landscape →
Q54RB7 — 0.990 Q54RB7 →
P29351 — 0.990 P29351 →
P97504 — 0.990 P97504 →
PTPN6 Tyrosine-protein phosphatase non-receptor type 6 0.990 landscape →
Q07407 — 0.989 Q07407 →
O13147 — 0.989 O13147 →
Q54Y55 — 0.989 Q54Y55 →
Q8VZD5 — 0.988 Q8VZD5 →
O01798 — 0.988 O01798 →
DCLK1 Serine/threonine-protein kinase DCLK1 0.988 landscape →
P35991 — 0.988 P35991 →
P42682 — 0.988 P42682 →
O12990 — 0.988 O12990 →
P70600 — 0.988 P70600 →
P42159 — 0.988 P42159 →
Q9H1H9 — 0.988 Q9H1H9 →
Q09639 — 0.987 Q09639 →
Q24145 — 0.987 Q24145 →
Q60629 — 0.987 Q60629 →
P00528 — 0.987 P00528 →
P10686 — 0.987 P10686 →
Q05688 — 0.987 Q05688 →